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Abstract
Background: Whole genome sequencing (WGS) of Cryptosporidium spp. has previously relied on propagation of the
parasite in animals to generate enough oocysts from which to extract DNA of sufficient quantity and purity for analysis.
We have developed and validated a method for preparation of genomic Cryptosporidium DNA suitable for WGS directly
from human stool samples and used it to generate 10 high-quality whole Cryptosporidium genome assemblies. Our
method uses a combination of salt flotation, immunomagnetic separation (IMS), and surface sterilisation of oocysts prior
to DNA extraction, with subsequent use of the transposome-based Nextera XT kit to generate libraries for sequencing on
Illumina platforms. IMS was found to be superior to caesium chloride density centrifugation for purification of oocysts
from small volume stool samples and for reducing levels of contaminant DNA.
Results: The IMS-based method was used initially to sequence whole genomes of Cryptosporidium hominis gp60 subtype
IbA10G2 and Cryptosporidium parvum gp60 subtype IIaA19G1R2 from small amounts of stool left over from diagnostic
testing of clinical cases of cryptosporidiosis. The C. parvum isolate was sequenced to a mean depth of 51.8X with reads
covering 100 % of the bases of the C. parvum Iowa II reference genome (Bioproject PRJNA 15586), while the C. hominis
isolate was sequenced to a mean depth of 34.7X with reads covering 98 % of the bases of the C. hominis TU502 v1
reference genome (Bioproject PRJNA 15585).
The method was then applied to a further 17 stools, successfully generating another eight new whole genome
sequences, of which two were C. hominis (gp60 subtypes IbA10G2 and IaA14R3) and six C. parvum (gp60 subtypes
IIaA15G2R1 from three samples, and one each of IIaA17G1R1, IIaA18G2R1, and IIdA22G1), demonstrating the utility of this
method to sequence Cryptosporidium genomes directly from clinical samples. This development is especially important as
it reduces the requirement to propagate Cryptosporidium oocysts in animal models prior to genome sequencing.
Conclusion: This represents the first report of high-quality whole genome sequencing of Cryptosporidium isolates
prepared directly from human stool samples.
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Background
Cryptosporidium is a genus of protozoan parasites which
are a major cause of gastrointestinal infection worldwide.
Symptoms of human cryptosporidiosis include diarrhoea ab-
dominal pain, nausea or vomiting and low grade fever.
These are usually self-limiting, albeit after 2 or even 3 weeks,
but can be prolonged or invasive and life-threatening in pa-
tients with severe T-cell immune-deficiency [1]. Cryptospor-
idium spp. are also increasingly recognised as an important
cause of childhood morbidity and mortality in developing
countries [2]. Treatment options are limited, with only one
specific licenced therapeutic. Of the 26 Cryptosporidium
spp. currently named, Cryptosporidium hominis and Crypto-
sporidium parvum are the most common causes of crypto-
sporidiosis in humans globally. Research into the biology of
the organism has been partly hampered by the lack of an ef-
fective cell culture system for propagation and the limited
availability of genomic sequence data, impacting, for ex-
ample, on progress in understanding the taxonomic position
of the protozoan, therapeutic drug discovery, and identifica-
tion of diagnostic, virulence and subtyping markers.
Whole genome sequences produced using Sanger sequen-
cing techniques, are publically available for single isolates of
three species which have historically provided reference ge-
nomes for the mainly anthroponotic C. hominis (isolate
TU502), the zoonotic C. parvum (isolate IOWA II), and
C. muris (isolate RN66) which primarily infects rodents
[3, 4]; NCBI BioProjects: PRJNA15585 PRJNA15586,
PRJNA32283). Recently, new whole genome sequences
have been made available from next generation se-
quencing (NGS) platforms, providing updated versions
of the genome sequences for C. hominis TU502 and C.
parvum IOWA II and new genome sequences for add-
itional isolates: C. hominis UKH1, C. meleagridis UKMEL1
and C. baileyi TAMU-09Q1 (www.cryptoDB.org). The
powerful technologies provided by NGS have dramatic-
ally reduced the cost and time required for whole gen-
ome sequencing, greatly increasing our knowledge of
Cryptosporidium spp. by, for example, allowing in-
depth, high-resolution comparison of isolates and deep
sequencing of selected loci for investigation of parasite
population variability. However, significant challenges
exist for generation of whole genome sequence data,
largely because even the most sensitive sample prepar-
ation kit for the generation of sequencing libraries de-
mands at least 1 ng genomic DNA; C. parvum oocysts
each contain 40 fg DNA [5] thus requiring an estimated
2.5 × 104 highly-purified oocysts. Human stool samples
received at diagnostic laboratories tend to be small in
volume and contain relatively small numbers of Crypto-
sporidium oocysts amongst very large numbers of non-
target organisms, mainly bacteria, which is problematic
for the production of the purity of genomic DNA re-
quired for analysis. Whole genome sequences generated
to date have either utilised experimental animal infections
for propagation of sufficient material [6] or obtained and
processed large volumes of animal faeces from natural in-
fections [7]; both approaches restrict the information avail-
able to a small number of sufficiently abundant isolates
and may introduce the potential for strain selection bias.
The former is most especially unsustainable for large-scale
investigations for practical, financial and ethical reasons,
particularly for C. hominis which has no symptomatic ani-
mal model and requires passage in gnotobiotic piglets [8]
or immunosuppressed Mongolian gerbils [9]. Enrichment
of genomic Cryptosporidium DNA for WGS from stools
has recently been described using whole genome amplifica-
tion but significant contamination was reported [10].
Here we describe the development and validation of a
protocol for preparation of genomic Cryptosporidium DNA
from routinely submitted diagnostic human stool samples
suitable for whole genome sequencing. The method has the
following characteristics which specifically address the
challenges described above: enhanced purification of
oocysts degradation of non-Cryptosporidium contaminants,
and use of an NGS library preparation kit capable of pro-
cessing as little as 1 ng of genomic DNA.
Results and discussion
Characterisation of isolates prior to WGS
Characterisation by C. parvum and C. hominis-specific real-
time polymerase chain reaction (PCR) revealed no evidence
of the presence of more than one species in any of the stools
tested. Only the expected species were identified by Sanger
sequence analysis of the 18S rRNA actin, hsp70 and COWP
genes. Gp60 subtypes were identified as shown in Tables 1
and 2. There was no evidence from the sequencing chro-
matograms that any of the isolates were of mixed popula-
tions of Cryptosporidium species or gp60 subtypes.
Evaluation of oocyst preparation methods in the pilot
phase
Salt-floated suspensions of 1 × 106 C. parvum and C. homi-
nis oocysts yielded after IMS, 6.1 × 105 (61 % recovery) and
4.5 × 105 oocysts (45 % recovery, respectively. After bleach-
treatment, 3.7 × 105 C. parvum and 2.9 × 105 C. hominis
oocysts were counted, sufficient for DNA extraction.
Caesium Chloride (CsCl) density gradient centrifugation
of the same original number of oocysts in salt-floated sus-
pension yielded 2×105 C. parvum oocysts (20 % recovery)
and <2 × 104 C. hominis oocysts (<2 % recovery undetect-
able in counting chamber) and after bleach treatment
1.3 × 105 and <5.3 × 103 (undetectable), respectively, indi-
cating that IMS was the more efficient method for purifica-
tion of oocysts derived from small volume stool samples
(Table 1). Due to undetectable numbers of oocysts in the
CsCl-prepared C. hominis suspension, this was not proc-
essed further. Although CsCl has been used successfully
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for oocyst preparation from bulk samples collected repeat-
edly from a naturally infected animal [7], the collection of
bulk or multiple repeat samples is not practical for stool
collection from most human patients.
The use of quantitative PCR (qPCR) to derive oocyst
numbers in the salt-floated suspensions resulted in esti-
mates 9.4-fold (C. parvum) and 8.6-fold (C. hominis) lower
than those derived from microscopic counts of intact
oocysts in good condition (Table 1). Either Cryptosporid-
ium DNA was lost during the extraction process or there
was uncertainty of the measurements. The presence of
PCR inhibitors co-extracted with the DNA would be ex-
pected to lead to an underestimation of DNA concentration
by qPCR in these stool-derived samples when compared to
standard curves derived from cloned template. Oocyst
numbers derived from qPCR of DNA extracted from the
more highly-purified IMS and CsCl suspensions were
closer to actual microscopic counts than those for the salt-
floated suspensions (Table 1); it is likely that DNA from
more highly-purified oocysts was more closely represented
by the standard curve plasmid DNA and therefore more ac-
curately quantified than that prepared from the salt-floated
suspensions.
A substantial decrease in the mass of bacterial DNA was
identified after both IMS and bleach-treatment (Table 1)
reduced by 94.9 % (C. hominis) and 98.7 % (C. parvum)
compared with the salt-floated suspensions. CsCl-prepared
C. hominis DNA was not processed for library preparation
due to its low total DNA concentration (see below). Total
DNA concentration in the DNA extracts from the C. par-
vum IMS and CsCl-prepared samples and the C. hominis
IMS-prepared sample, measured by Qubit fluorometric
quantitation, was >1 ng and therefore sufficient for NGS li-
brary preparation.
These measurements highlighted the utility of the IMS
and bleaching processes for reduction of extraneous DNA
without significantly affecting the amount of Cryptosporid-
ium DNA. Seth-Smith et al. also used IMS to reduce non-
target organisms prior to Chlamydia trachomatis DNA
extraction [11] however, in the case of Cryptosporidium, the
oocyst wall affords the opportunity to further reduce bacter-
ial contamination with brief sodium hypochlorite treatment
without damaging the target DNA, whilst providing chal-
lenges with regard to fracturing the oocyst wall prior to
DNA extraction when dealing with low numbers of oocysts.
Evaluation of DNA preparation in the main phase
Of the 17 stools processed nine produced sufficient total
DNA for library preparation, of which two contained C.
hominis and seven C. parvum. The median low threshold
cycle (CT) value for suspensions that generated sufficient
DNA for whole genome sequencing (27.3, range 23.5-30.9)
was significantly lower than for those that did not (30.5,
range 28.1-34.0) (p = 0.009). Although there was some over-
lap in CT values, suspensions containing oocysts that were
in good condition were more likely to produce whole gen-
ome sequences (Table 2). Although qPCR was not a reliable
indicator of oocyst abundance in salt floated suspensions in
the pilot phase, the combination of qPCR, oocyst counts
and visual condition proved to be a good and practical
predictor of suitability of salt-floated suspensions for further
processing in the main phase (Table 2 Fig. 1). The import-
ance of microscopic examination is notable because al-
though oocyst counts are time consuming so is IMS
processing (which is also expensive), and pre-screening in
this way would maximise use of resources in larger scale
applications. Post IMS there was clear delineation of CT
values between sufficient and insufficient preparations the
Table 1 Properties of Cryptosporidium oocyst and DNA preparations from two pilot phase stool samples
Isolate, species
and gp60
subtype
Preparation stage qPCR 18S
rRNA gene (CT)
from original
stool sample
Quantification of Cryptosporidium
processed by IMS
Bacterial DNA calculated
from qPCR 16 s rRNA
gene (ng) (% reduction
compared with salt-floated
suspension)
Total DNA
from Qubit (ng)
Numbers of oocysts
counted; genome copies
derived from microscopy
counts
Genome copies
calculated from
qPCR 18 s rRNA
gene
UKP2, C. parvum
IIaA19G1R2
Salt-floated
suspension
28.8 1.0 ×106; 4.0×106 4.27×105 323.1 ND
Post IMS, bleach
treated suspension
3.7×105; 1.5×106 2.99×105 4.2 (98.7 % reduction) 2.44
Post CsCl, bleach
treated suspension
1.3×105; 5.2 ×105 1.99×105 NDa 1.52
UKH3, C. hominis
IbA10G2
Initial suspension 26.7 1.0×106; 4.0×106 4.6×105 86.7 ND
Post IMS, bleach
treated suspension
2.9×105; 1.2×106 1.3×106 4.4 (94.9 % reduction) 2.68
ND, not done
aNot tested in order to preserve DNA as total DNA level was low
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Table 2 Assessment of Cryptosporidium preparation from 17 stool samples containing C. hominis or C. parvum oocysts
Initial suspension prior to processing by IMS DNA extracted from IMS purified oocysts
Sample Species and gp60 subtype qPCR 18S rRNA CT Number of
oocysts counted
Visual condition of oocysts qPCR 18S rRNA CT Calculated
genome copies
Mass of
DNA (ng)
>1 ng DNA available
for library preparation
(isolate reference number)
1 C. hominis IaA14R3 ND 1.9×107 Good 17.7 5.53×107 77 Yes (UKH4)
2 C. hominis IbA10G2 23.5 1.6×107 Good 20.0 1.24×107 49.55 Yes
(UKH5)
3 C. hominis IdA18 29.3 2.1×105 Good 25.7 1.64×105 Below
threshold
No
4 C. parvum IIaA15G1R1 31.6 7.5×104 Good 25.9 1.49×105 0.00 No
5 C. parvum IIaA15G1R2 31.1 5.0×104 Good 25.1 2.36×105 0.00 No
6 C. parvum IIaA15G2R1 28.1 3.6×105 OK - a few empty oocysts,
didn't stain well
28.6 2.66×104 0.00 No
7 C. parvum IIaA18G2R1 29.1 1.5×106 Good 22.2 2.99×106 5.45 Yes
(UKP3)
8 C. parvum IIaA15G2R1 25.5 2.8×106 Good 20.1 5.99×106 18.65 Yes
(UKP4)
9 C. parvum IIaA15G2R1 27.5 9.1×105 Good 23.2 1.52×106 2.68 Yes
(UKP5)
10 C. parvum IIaA15G2R1 27.1 2.7×106 Good 23.4 1.32×106 4.40 Yes
(UKP6)
11 C. parvum IIaA17G1R1 23.8 9.0×106 Good 20.3 1.01×107 28.65 Yes
(UKP7)
12 C. parvum IIaA19G2R1 30.4 1.1×106 Good 24.4 3.74×105 0.8 No
13 C. parvum IIaA19G2R1 29.2 1.1×106 Good 28.7 2.53×104 0.00 No
14 C. parvum IIaA19G2R1 30.6 5.2×105 OK 31.8 3.58×103 0.00 No
15 C. parvum IIaA19G2R1 34.0 3.9×104 OK - a few empty oocysts No amplicon
detected
0 ND No
16 C. parvum IIdA22G1 28.4 2.3×106 Good 21.9 3.62×106 6.55 Yes
(UKP8)
17 C. parvum IIdA24G1 30.9 1.2×106 Good 23.9 1.01×106 2.88 Yesa
aA technical problem resulted in no data being produced for this sample
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median CT value for those that generated sufficient DNA
for whole genome sequencing (21.9 range 17.7-23.9) was
significantly lower than those that did not (25.9, range
24.4-31.8) (p = 0.0009). There was a significant relationship
between Cryptosporidium 18S rRNA gene qPCR and mass
of DNA in the final extracts (R2 = 8.315, see Fig. 2) indicat-
ing this comprised a sufficiently large proportion of Crypto-
sporidium DNA. Although 16S rRNA gene qPCR had
proved useful in the pilot phase to demonstrate reduction
in bacterial DNA, it was not used in the main phase.
Cryptosporidium 18S rRNA gene qPCR was evidently more
useful in process monitoring, with the pilot phase results
showing that Cryptosporidium genome copies could
more accurately be derived from these data, with the
additional benefit of reduced analysis preserving material
for downstream use.
Results of next generation sequencing
Including both pilot and main phases a total of three C.
hominis and seven C. parvum whole genomes were suc-
cessfully sequenced, reads aligned to reference genomes,
and contigs de novo assembled and annotated, with an
additional sequence generated via the CsCl method for
the C. parvum isolate in the pilot phase.
In the pilot phase sequencing C. parvum UKP2 using the
Illumina MiSeq achieved 100 % coverage of the C. parvum
IOWA II reference genome at a mean 51.80X depth using
the IMS-based method, 100 % coverage at a mean 46.84X
depth using the CsCl-based method, and for C. hominis
UKH3 98 % coverage of the C. hominis TU502 reference
genome at a mean 34.71X depth (Table 3). When aligned
to the reference genomes, 90.30 % of reads from C. homi-
nis UKH3, 92.51 % of reads from C. parvum UKP2 IMS
preparation and 81.86 % reads from C. parvum UKP2 CsCl
preparation mapped to the reference sequences the per-
centage of unmapped reads were likely from residual bac-
terial contamination (although this appears to be low) and
sequencing errors and was greater for the CsCl preparation
compared to the IMS preparations.
In the main phase eight of the nine DNA extracts gener-
ated high-quality data using the Illumina HiSeq the pro-
portion of reads mapping to the reference sequence
ranged from 80.90 % to 89.06 % with 0.96 to 0.99 fraction
of the reference genome covered confirming the suitability
of the Illumina Nextera XT sample preparation for gener-
ation of Cryptosporidium genomes from clinical isolates
(Table 3). One sample failed to produce sufficient data
probably because insufficient library DNA was added at
the pooling stage.
The post-assembly genome improvement protocol
(PAGIT) [12] improved assemblies produced from the
sequenced reads were of high-quality and statistics de-
scribing them are given in Table 4. Of the 10 assem-
blies 8 could be assembled into less than 70 scaffolds,
with the assembly N50 metric equal to just over 1 Mb
for most assemblies (i.e. 50 % of the genome has been as-
sembled into scaffolds with a minimum length of 1 Mb).
Using the Bowtie2 read aligner [13] with the default set-
tings we were able to align between 82.0 % and 96.2 % of
sequenced reads as concordant pairs to the final genome
assemblies, indicating that the genome assemblies are rela-
tively complete. Rapid annotation transfer tool (RATT)
[14] was able to transfer between 92.1 % and 95.9 % of the
3,805 gene annotations from C. parvum Iowa II to the as-
semblies thus providing a sound basis for further studies
into sequence and structural variation. Although notably
greater depth of coverage was achieved with the Illumina
HiSeq (26.9-209.2 X) than with the MiSeq, the MiSeq gen-
ome assemblies were nonetheless of equivalent quality: see
the statistics for UKH3 and UKP2 in Table 4.
In order to investigate the possibility of bacterial con-
tamination for each isolate, any read pairs that did not
map concordantly to the final de novo contig assemblies
were assembled separately. From these assemblies of
contaminants, contigs greater than 300 bp were blasted
Fig. 1 Relationship between total oocyst numbers, CT values and
concentration of recovered DNA. Oocyst numbers (counted by
microscopy), and CT values in the salt-floated suspension were
determined prior to processing, and compared to final DNA recovery.
Red, WGS successful; Blue, <1 ng DNA available (below manufacturer’s
threshold for library preparation)
Fig. 2 Relationship between Cryptosporidium genome copies and total
DNA in extracts prior to whole genome sequencing
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[15] against all Cryptosporidium assemblies available on
the National Center for Biotechnology Information (NCBI:
C. muris RN66, C. parvum Iowa II, Cryptosporidium sp.
chipmunk LX-2015, and C. hominis TU502) [16]. Using a
Basic Local Alignment Search Tool (BLAST) e-value < 1−10
potential Cryptosporidium sequences were filtered out of
these assemblies. The remaining non-Cryptosporidium
contigs (column “NC” in Table 4) were subsequently
blasted against all bacterial genomes available on the
NCBI, and using an e-value < 1−10 the total amount of
Table 3 Quality of whole genome sequences generated directly from stools containing C. hominis and C. parvum
Isolate; species and
gp60 subtype;
BioProject number
Total # base
pairs sequenced
(after merging reads)
Total # base
pairs mapped to
reference sequence
Proportion of
Cryptosporidium
DNA compared
to background
% of reference
genome covered
Mean depth
on reference
sequence
% AT content
of reads mapped
to reference
sequence
Pilot phase
UKH3
(IMS preparation)
337,791,948 305,024,423a 90.30 % 98 % 34.71 × 67.49 %
C. hominis IbA10G2
PRJNA253834
UKP2
(IMS preparation)
510,081,295 471,881,392b 92.51 % 100 % 51.80 × 67.92 %
C. parvum IIaA19G1R2
PRJNA253836
UKP2 (CsCl preparation) 521,277,984 426,692,177b 81.86 % 100 % 46.84 × 67.85 %
C. parvum IIaA19G1R2
PRJNA253836
Main phase
UKH4 2,164,426,378 1,828,866,488a 84.50 % 96 % 209.17 × 62.72 %
C. hominis IaA14R3
PRJNA253838
UKH5 2,182,317,271 1,765,458,438a 80.90 % 96 % 201.92 × 63.03 %
C. hominis IbA10G2
PRJNA253839
UKP3 1,703,132,267 1,514,828,932b 88.94 % 99 % 166.42 × 63.55 %
C. parvum IIaA18G2R1
PRJNA253840
UKP4 1,967,147,533 1,751,979,030b 89.06 % 99 % 192.48 × 63.60 %
C. parvum IIaA15G2R1
PRJNA253843
UKP5 288,922,509 244,528,063b 84.63 % 99 % 26.86 × 67.67 %
C. parvum IIaA15G2R1
PRJNA253845
UKP6 1,169,379,989 954,176,437b 81.60 % 99 % 104.83 × 67.73 %
C. parvum IIaA15G2R1
PRJNA253846
UKP7 795,715,168 708,613,859b 89.05 % 99 % 77.85 × 63.64 %
C. parvum IIaA17G1R1
PRJNA253847
UKP8 1,896,616,473 1,587,380,412b 83.70 % 98 % 174.39 × 63.20 %
C. parvum IIdA22G1
PRJNA253848
amapped against C. hominis TU502 v1 reference sequence (Bioproject PRJNA15585)
bmapped against the C. parvum IOWA II v1 reference sequence (Bioproject PRJNA15586) using default mapping conditions
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bacterial sequence was identified (column “BCT” in
Table 4). The amount of contaminating sequence was
too small, too fragmented (the longest contig from any
of these assemblies was 971 bp), or too low in complex-
ity to reliably identify any particular contaminating bac-
teria species.
The serine tri-nucleotide repeat rich gp60 gene se-
quence is used in sub-typing to study the taxonomy and
transmission of the Cryptosporidium parasite [17, 18].
Searching for the gp60 gene sequences from each isolate
in the respective assemblies with BLASTN produced
100 % alignments with an E-value = 0.0 of 681 to 755 bp
in length: although no alignments were reported over
the low complexity regions at the start of the gp60 gene
because BLAST filters out such regions before aligning
sequences. The 18S rRNA gene sequences were similarly
found by BLAST in the assemblies with 100 % sequence
identity, split into two alignments due a low complexity
region in the middle of the sequence with each align-
ment having a length of around 250 bp to 400 bp. Ex-
ceptions were UKH4, where two copies (i.e. four
alignments of 250 bp to 400 bp) of the 18S rRNA gene
region could be found, all between 99.2 % to 100.0 % se-
quence identity, and UKH5 where there were three
BLAST hits of 100.0 % sequence identity (also with
250 bp to 400 bp lengths). No evidence was found of
mixed species populations. Note that five copies of the
18S rRNA gene are found in the C. parvum Iowa II ref-
erence genome assembly and this indicates that the as-
sembly process used in this study has collapsed the 18S
rRNA gene regions, typically into just one copy.
The genome data from this study have been deposited on
the NCBI (http://www.ncbi.nlm.nih.gov/) database as indi-
vidual BioProjects (Table 3) under the umbrella BioProject
PRJNA215218.
Conclusions
We have developed a method for the high-quality se-
quencing of Cryptosporidium spp. isolates using the
transposome-based Nextera XT library preparation and
Illumina sequencing platform directly from routinely
submitted human stools left over from diagnostic test-
ing. This has the advantage of reducing the require-
ment for the use of animals for in vivo amplification of
oocysts to extract sufficient genomic Cryptosporidium
DNA for whole genome sequencing as was used to generate
the reference genomes [3, 4] and potentially extending the
possibilities for more widespread investigation of Crypto-
sporidium. The generation and comparison of benchmark
genomes from all Cryptosporidium species and genotypes
would help establish more definitive taxonomy than is cur-
rently possible based on the analysis of only a tiny propor-
tion of the genome using Sanger sequencing even of
multiple loci [19]. Global surveillance and analysis of
Cryptosporidium genomes from widespread and repre-
sentative infections would be valuable for identification
of possible drug targets, new diagnostic, virulence and
subtyping markers.
The samples prepared in this study were chosen because
of sufficient sample volume (1 to 2 ml) and adequate con-
centration of oocysts in the salt-floated suspension. Even
so the concentration of DNA available after the purifica-
tion processes was often at the limit of that acceptable for
the Illumina technology used. It is evident that to extend
the utility of Illumina sequencing to stools of smaller vol-
umes or with lower concentrations of oocysts, strategies
such as the application of kits requiring <1 ng DNA would
be useful, as might whole genome amplification (WGA)
which has proven capable of increasing genomic DNA in
Cryptosporidium samples [20] and may be of use for pro-
ducing sufficient material [10, 11].
Table 4 Summary of improvements made to the initial genome assemblies by PAGIT
Isolate Initial assembly
statistics: No.
N50 Av. (kb)
Gaps closed
by IMAGE
ICORN Sequence
corrections:
SNP Indel
RATT Gene
annotations transferred
Final assembly
statistics: No.
N50 Av. Size (kb)
Paired reads
aligning
concordantly (%)
Contaminant
sequence NC
BCT (kb)
UKH3 1902 94.7 4.9 330 210 27 3649 34 1000 268.7 9136 87.5 41.1 0.0
UKH4 2375 29.1 4.0 343 584 99 3503 110 1032 84.4 9293 93.5 40.1 14.1
UKH5 1305 29.9 7.0 437 189 61 3569 65 1006 142.4 9257 96.2 6.9 2.4
UKP2 3084 105.2 3.1 174 182 48 3600 67 1011 136.7 9164 85.1 89.6 1.6
UKP3 919 57.5 10.0 259 226 60 3546 55 1009 167.7 9224 90.2 2.0 0.0
UKP4 1966 49.3 4.8 334 170 108 3553 52 891 177.4 9222 91.0 7.3 0.7
UKP5 3830 9.7 2.4 1435 341 80 3527 47 1031 198.4 9329 88.6 31.4 14.6
UKP6 16895 40.3 0.8 274 3144 394 3565 417 1014 22.7 9471 81.2 685.7 69.5
UKP7 1158 30.2 7.8 321 185 80 3556 55 1026 168.7 9278 90.4 2.5 0.0
UKP8 1792 42.0 5.2 356 152 47 3545 63 1015 147.4 9290 93.5 37.9 24.4
The assembly statistics (initial and final) include the number of scaffolds, scaffold N50 metric, scaffold mean length (Av.), and the total size of the final assembly.
Gene annotations were transferred by RATT out of a total of 3805 gene annotations in the reference assembly. The “Contaminant sequence” column refers to the
total length non-concordantly mapping read pairs that have been assembled separately and identified as non-cryptosporidium sequence (NC) and bacterial
sequence (BCT)
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We are currently using this technique to compare
Illumina sequencing libraries generated from native and
WGA-amplified DNA from clinical samples [Pachebat
personal communication]. This allows the approaches
to be compared and investigated for artifactual muta-
tions that, for example, have been reported to occur at
a rate of approximately 1 in 105 to 106 for φ29-based
methods [21]. Although it required additional steps and is
susceptible to contamination, WGA could expand the ap-
plication of Illumina sequencing to still more samples [10].
We conclude that in our laboratory using the current
Nextera XT library preparation methods the following se-
lection criteria are valuable predictors of likely successful
generation of high-quality C. parvum or C. hominis gen-
ome sequences from stool samples:
 Original stool sample volume >1 ml
 Initial salt-floated oocyst suspension 18S rRNA gene
qPCR CT < 30.9 AND >9×10
5 oocysts that are in
good condition with very few empty oocysts
 Post-IMS-bleach treatment 18S rRNA gene qPCR
CT < 24.0 and Qubit result >1 ng total DNA
However in other laboratories different factors (such
as PCR efficiency) may affect measurements, and the use
of different criteria may be necessary.
We have described the generation of high-quality se-
quences of Cryptosporidium directly from stool samples
and assembled these into 10 high-quality draft genomes.
Our method coupled with the availability of reference
sequences for comparison, removes the requirement for
the use of animals to passage and amplify oocyts prior
to genome sequencing. It reduces the cost, and extends
the potential for this technology to be applied to the
rapid and accurate genomic characterisation of clinical
isolates, for the purposes of control of transmission, and
treatment during outbreaks.
Methods
Source and characterisation of Cryptosporidium oocysts
The work was undertaken in two phases: a pilot phase
in which two stools were processed, and a main phase in
which a further 17 stools were processed.
In the pilot phase of the project, two Cryptosporidium-
positive stool samples submitted for diagnosis of diarrhoea
and subsequent identification of Cryptosporidium spp. were
selected using the criteria of volume ≥1 ml and adequate
oocyst numbers indicated by low threshold cycle (CT) in an
18S rRNA gene real-time PCR assay [22] (Table 1). Crypto-
sporidium species were identified by Sanger sequence ana-
lysis of the ~300 bp fragment of the 18S rRNA gene and
each sample confirmed as containing either C. parvum or
C. hominis only using a species-specific multiplex genotyp-
ing real-time PCR targeting the C. parvum Lib13 and C.
hominis A135 loci [22, 23] Cryptosporidium Reference Unit
unpublished). Gp60 subtypes were identified by sequen-
cing ~850 bp of the gp60 gene [18]. Additional Sanger
sequence data was obtained for the actin, hsp70 and
Cryptosporidium oocyst wall protein (COWP) genes as
described previously [24].
In the main phase of the project, 17 further samples
meeting the stool selection criteria above, and having a
range of gp60 subtypes, were selected for purification
and processing; three containing C. hominis and 14 C.
parvum (Table 2).
Ethics statement: The protozoal isolates were collected
as part of routine clinical service provision [25]. The study
of de-identified, purified protozoal DNA and not human
subjects meant that formal Human Ethics Committee ap-
proval or Informed Patient Consent was not required.
Purification of Cryptosporidium oocysts
Cryptosporidium oocysts were harvested from 1 to 2 ml
of each faecal sample using saturated salt-flotation to
generate a partially purified suspension as described
previously [25]. The number of oocysts in these sus-
pensions was estimated by staining with equal volume
of FITC-labelled anti-Cryptosporidium monoclonal antibody
(Crypto-Cel, Cellabs, Australia) and counting using a Neu-
bauer improved haemocytometer (C-Chip, Peqlab, Sarisbury
Green, UK).
Oocysts were further purified from suspension by immu-
nomagnetic separation (IMS). In the pilot phase, a total of
1×106 salt-floated oocysts were made up to 10 ml with re-
verse osmosis (RO) water and processed through the Iso-
late® IMS kit (TCS Biosciences, Botolph Claydon, UK)
according to the manufacturer’s instructions. Oocysts were
dissociated from the magnetic beads into 1.5 ml microfuge
tubes (Elkay, Basingstoke, UK), and the volume adjusted to
1 ml with RO water prior to surface sterilisation. In the
main phase salt-floated oocysts were treated similarly, but
all available oocysts were used (ranging from 3.9×104 to
1.9×107, see Table 2) and dissociated oocysts adjusted to
200 μL with RO water prior to surface sterilisation.
To investigate an alternative to IMS in the pilot phase,
1×106 oocysts were also purified from the salt-floated sus-
pensions by caesium chloride (CsCl) gradient centrifugation
as described by Upton [26], the final pellets resuspended to
1 ml in RO water and oocysts enumerated by microscopy
as described above prior to surface sterilisation.
Surface sterilisation of Cryptosporidium oocysts
To degrade residual contaminants, each purified oocyst
suspension was treated briefly with an equal volume of
0.6 % active chlorine as sodium hypochlorite (VWR,
Lutterworth, UK) and washed three times with nuclease-
free water by centrifugation at 1,100X g for 5 min using
a swing rotor and soft acceleration-deceleration profile
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to minimise damage to oocysts. The pellets were finally
resuspended in 215 μL of nuclease-free water, 15 μL used
for oocyst enumeration as described above and 200 μL for
DNA extraction.
DNA preparation and characterisation
Genomic DNA was prepared from 200 μL final Cryptospor-
idium oocyst suspensions by first performing eight cycles of
freezing in liquid nitrogen for 1 min and thawing at 95 °C
for 1 min, and then using the QIAamp DNA extraction kit
(Qiagen, Manchester, UK) according to the manufacturer’s
instructions and finally eluting in 50 μL nuclease-free water.
Maximum recovery tips (Axygen Inc, USA) and DNA
LoBind tubes (Eppendorf AG, Germany) were used in
all subsequent DNA quantification and sequencing li-
brary preparation steps.
To investigate the efficacy of Cryptosporidium purifi-
cation in the pilot phase, bacterial, Cryptosporidium and
total DNA concentrations were measured as described
below in 50 μL samples taken from intermediate stages
of the oocyst purification process and extracted as de-
scribed above, as well as in the final DNA extracts. To
assess suitability for NGS library preparation in the main
phase of the study, all final extracts were assayed for
total DNA concentrations and specific quantification of
Cryptosporidium DNA as described below.
Estimation of bacterial load was performed by real-
time quantitative (q)PCR of the 16S rRNA gene using
neat genomic DNA against standards created as de-
scribed by Jones et al. [27], except that a pure culture of
Escherichia coli was used as template material. Serial di-
lutions of 100, 10−2, 10−4, 10−6, 10−8 and 10−10 were used
in subsequent qPCR reactions using a C100 thermal cycler
(BioRad, Hercules, USA) and CFX96 optical detector
(BioRad). Reactions were completed in 20 μL volumes
consisting of 10 μL of SsoAdvanced SYBR Green Supermix
(BioRad) at a final concentration of 1x, 400 nM of each of
the forward and reverse primers, as described by Kim et al.
[28], and 3 μL of genomic DNA. The final volume was
made up with PCR grade water (Roche Diagnostics
Limited, West Sussex, UK).
Total DNA concentration in genomic DNA extracts was
measured using the Qubit dsDNA HS Assay Kit with the
Qubit 1.0 fluorometer (Invitrogen, Paisley, UK) according to
the manufacturer’s instructions. A mass of >1 ng DNA per
extract was required for the Nextera XT library preparation
(Illumina, Little Chesterford, UK). DNA samples below
0.2 ng μL−1 were concentrated by evaporation (SpeedVac,
Thermo Scientific, Loughborough, UK), then resuspended
in ultrapure water (Illumina) to 0.2 ng μL−1 for subsequent
library preparation.
Specific quantification of Cryptosporidium DNA was per-
formed by qPCR of the 18S rRNA gene using a protocol
modified from Hadfield et al., [22]; only primers CRU18SF
and CRU18SR (Integrated DNA Technologies, Glasgow,
UK) at 900 nM, and the carboxyfluorescein-labelled minor
groove binding TaqMan probe CRU18STM (Applied Bio-
systems, Warrington, UK) at 100 nM, were included. DNA
concentration was estimated by comparing sample CT
with a standard curve created by testing linearised plasmid
clones of the C. hominis 18S rRNA target region [22] seri-
ally diluted ten-fold in nuclease-free water, providing 101
to 107 copies per reaction. Each oocyst DNA extract was
tested in triplicate and mean concentration calculated. CT
values were recorded and converted to oocyst equivalents
mL−1 based on published evidence that each oocyst con-
tains 20 copies of the 18S rRNA gene [29].
CT values from initial suspensions and fully purified
DNA were compared using a Mann–Whitney U test
(Epi-info version 6, Centers for Disease Control and Pre-
vention, USA). The reliability of the linear relationship
between genome copies and mass of DNA in the final
purified DNA extracts was measured by calculating the
correlation coefficient (MS Excel).
Next Generation Sequencing and Analysis
Barcoded paired-end libraries were created for each isolate
with 1 ng of DNA using the Nextera XT DNA sample
preparation kit (Version C protocol, Illumina). Ampli-
cons >500 bp were size selected in the post-PCR purifi-
cation steps. The resulting Nextera XT libraries were
very low concentration, so after quantification by Qubit
HS DNA assay, were pooled to give a 0.1 nM concentration
and concentrated using a SpeedVac. In the initial phase, the
Nextera XT libraries were sequenced on a MiSeq (Illumina)
using 2 × 151 bp reads. In the main phase, libraries were se-
quenced on a HiSeq 2500 (Illumina) using a 2 × 151 bp
rapid run.
Bioinformatics analysis was performed using CLC
Genomics Workbench version 7.04 (CLC Bio, Aarhus,
Denmark). Briefly, reads were paired, overlapping reads
within a read pair merged, and trimmed based on a quality
limit of 0.05, with a maximum of 2, ambiguities. To check
sequencing coverage and depth, reads were subsequently
mapped to the appropriate contemporaneous reference ge-
nomes, C. hominis TU502 v1 (Bioproject PRJNA 15585)
and C. parvum Iowa II v1 (Bioproject PRJNA 15586)
using CLC Genomics Workbench default settings (Masking
mode = no masking, Mismatch cost = 2, Insertion cost = 3,
Deletion cost = 3, Length fraction = 0.5, Similarity frac-
tion = 0.8, Global alignment = No, Auto-detect paired
distances = Yes, Non-specific match handling =Map
randomly). Reads were also mapped to the C. hominis
and C. parvum reference genomes using the Bowtie2
read aligner [13], with default settings, to the follow-
ing quality parameters: high sequence identity and
similar GC content (~30 %) to the reference genomes,
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a high-proportion of target DNA compared to back-
ground, and at least 30 X average sequencing depth.
De novo contig assembly for each isolate was performed
using CLC Genomics Workbench (Mapping Mode = Cre-
ate simple contig sequences, Automatic bubble size = Yes,
Minimum contig length = 200 bp, Automatic word
size = Yes, Perform scaffolding = Yes, Autodetect paired
distances = Yes, Min distance = 180 bp, Max distance =
500 bp). The CLC de novo contig assemblies were im-
proved using the post-assembly genome improvement
protocol, PAGIT [12]. In brief, scaffolds were ordered
using algorithm based automatic contiguation of assem-
bled sequences (ABACAS) [30] against the C. parvum
Iowa II reference genome; this genome comprises 18
contigs and mapping the assemblies to it generated 18
pseudomolecules that contained most of the assembled
sequences, with typically 100 to 200 further much
smaller scaffolds that could not be associated with the
reference genome. Next, iterative mapping and assem-
bly for gap elimination (IMAGE) [31] was used to close
sequencing gaps in scaffolds of at least 500 bp. Smaller
scaffolds were removed at this stage. Iterative Correc-
tion of Reference Nucleotide (ICORN) [32] was then
used to correct single-base errors and small insertions
and deletions of up to 3 bp. Lastly, the C. parvum Iowa
II annotation was transferred onto the 18 pseudomole-
cules using rapid annotation transfer tool (RATT) [14].
The improvements made to the CLC assemblies using
the PAGIT protocol were documented and are sum-
marised in Table 4.
Availability of supporting data
Whole genome sequencing data is deposited on the Na-
tional Centre for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/) GenBank database as individual
BioProjects (PRJNA253834, PRJNA253836, PRJNA253838-
PRJNA253840, PRJNA253843, PRJNA253845-PRJNA2538
48) under the umbrella Bioproject PRJNA215218. 18S rRNA,
gp60, hsp70, COWP and actin gene Sanger sequences
are deposited under accession numbers KM085018-
KM085027, KM012040-KM012055 and KP280061.”
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